Prostatype Genomics AB (OSTO:PROGEN) YoY EBITDA Growth : 82.13% (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Prostatype Genomics AB's YoY EBITDA Growth for the quarter that ended in Jun. 2023 was 82.13%.

Prostatype Genomics AB's EBITDA per Share for the three months ended in Jun. 2023 was kr-0.05.

Prostatype Genomics AB YoY EBITDA Growth Historical Data

The historical data trend for Prostatype Genomics AB's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB YoY EBITDA Growth Chart

Prostatype Genomics AB Annual Data

Trend

Jun18

Jun19

Dec21

Dec22

Dec23

YoY EBITDA Growth

14.01

-23.60

-569.09

68.07

Prostatype Genomics AB Quarterly Data
	Jun18	Jun19	Mar20	Jun20	Sep20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial											-97.56	11.11	5.56	82.13	100.00

Prostatype Genomics AB YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Prostatype Genomics AB's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-0.47	-	-1.472)	/	\| -1.472 \|
=	68.07 %

Prostatype Genomics AB's YoY EBITDA Growth for the quarter that ended in Jun. 2023 is calculated as:

	YoY EBITDA Growth (Q: Jun. 2023 )
=	(EBITDA per Share (Q: Jun. 2023 )	-	EBITDA per Share (Q: Jun. 2022 ))	/	\| EBITDA per Share (Q: Jun. 2022 )) \|
=	(-0.052	-	-0.291)	/	\| -0.291 \|
=	82.13 %

Prostatype Genomics AB YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Prostatype Genomics AB (OSTO:PROGEN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

PGO:Germany

Address

Gustaf III:s Boulevard 34, Solna, SWE, 169 73

Website

https://www.prostatypegenomics.com

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines